you are here: Home News Habil Khorakiwala

Habil Khorakiwala

Wockhardt applies to seek USFDA nod for ‘miracle’ antibiotic Zaynich
Drug maker Wockhardt rallies over 9 percent as White House exempts pharma imports from nations with trade pacts
Wockhardt rises 10% after antibiotic Zaynich, undergoing clinical trials, facilitates in a liver transplant
Wockhardt, Serum Institute to invest and share profit equally from new UK jab plant: Habil Khorakiwala
Wockhardt partners with UK govt for COVID-19 vaccines
Wockhardt antibiotic expected to hit US in FY21, market worth $1.5 bn: Khorakiwala
No scope of US intervention in Indian pharma cos: Wockhardt
USFDA issues warning letter to Wockhardt's Ankleshwar plant
Won't be ethical for pharmas to bring back banned drugs: Expert
CP Pharma under FDA lens, will reply in 3 weeks: Wockhardt Chief
IACC Convention: Pharma & the USFDA jigsaw
Need to speed up process of granting patents: Khorakiwala
R&D tax deduction unlikely to impact Wockhardt: CEO
All 9 USFDA observations will be resolved in 3 months: Wockhardt
Will not do any out-licensing in near-term: Wockhardt
Wockhardt gets USFDA nod to market pain-relieving drug
Wockhardt hopeful of early resolution of USFDA row
Wockhardt hopes to resolve FDA ban on two plants in FY16
Hopeful of US FDA issue getting resolved soon: Wockhardt
Expect US FDA to visit remaining facilities soon: Wockhardt
Meet the Khorakiwalas: Gen-Next promoters of Wockhardt
Biggest Gainers and Losers on India Rich List 2013
Q2 earnings hit by recent regulatory actions: Wockhardt
UK regulator issues import alert on Wockhardt's Waluj plant
Wockhardt says USFDA import alert could impact biz by $100m

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Habil Khorakiwala

Wockhardt applies to seek USFDA nod for ‘miracle’ antibiotic Zaynich

Drug maker Wockhardt rallies over 9 percent as White House exempts pharma imports from nations with trade pacts

Wockhardt rises 10% after antibiotic Zaynich, undergoing clinical trials, facilitates in a liver transplant

Wockhardt, Serum Institute to invest and share profit equally from new UK jab plant: Habil Khorakiwala

Wockhardt partners with UK govt for COVID-19 vaccines

Wockhardt antibiotic expected to hit US in FY21, market worth $1.5 bn: Khorakiwala

No scope of US intervention in Indian pharma cos: Wockhardt

USFDA issues warning letter to Wockhardt's Ankleshwar plant

Won't be ethical for pharmas to bring back banned drugs: Expert

CP Pharma under FDA lens, will reply in 3 weeks: Wockhardt Chief

IACC Convention: Pharma & the USFDA jigsaw

Need to speed up process of granting patents: Khorakiwala

R&D tax deduction unlikely to impact Wockhardt: CEO

All 9 USFDA observations will be resolved in 3 months: Wockhardt

Will not do any out-licensing in near-term: Wockhardt

Wockhardt gets USFDA nod to market pain-relieving drug

Wockhardt hopeful of early resolution of USFDA row

Wockhardt hopes to resolve FDA ban on two plants in FY16

Hopeful of US FDA issue getting resolved soon: Wockhardt

Expect US FDA to visit remaining facilities soon: Wockhardt

Meet the Khorakiwalas: Gen-Next promoters of Wockhardt

Biggest Gainers and Losers on India Rich List 2013

Q2 earnings hit by recent regulatory actions: Wockhardt

UK regulator issues import alert on Wockhardt's Waluj plant

Wockhardt says USFDA import alert could impact biz by $100m